Rituximab outperformed steroids in Graves’ ophthalmopathy

SAN JUAN, Puerto Rico — Despite data presented earlier at the American Thyroid Association Annual Meeting showing that rituximab was not effective in treating Graves’ ophthalmopathy, another presenter here said that the drug does improve disease state when compared with methylprednisolone.“Response to rituximab was as high as 93%, compared to 69% observed after IV steroid,” Mario Salvi, MD, from the University of Milan in Italy, said. “Preliminary evidence of NOSPECS class 2 signs shows improvement after rituximab.”

Full Story →